A new diagnostic health testing and screening venture has been established at a North West science and innovation campus with an initial investment of more than £1m.
Sankey Biolabs is based at The Innovation Centre at Sci-Tech Daresbury in the Liverpool City Region and is headed by laboratory manager Frank Whitfield, who leads a team of biomedical scientists and support staff. New staff will be recruited as demand grows.
The Sankey Biolabs laboratory provides diagnostic blood testing services to a range of companies, organisations and occupational health specialists, with a focus on the health and wellbeing of employees nationwide.
Its initial array of blood testing profiles ranges from immunity screens for blood-borne viruses such as hepatitis B, hepatitis C and HIV, through to health screens such as kidney, liver and lipid profiles. This is as well as specific tests for cardiac risk, pre-diabetes and vitamin D deficiency.
The laboratory is offering results on the same day that samples are received.
Frank Whitfield said: "We have ambitious growth plans and we are well-positioned to expand and react rapidly to client requests by offering bespoke testing opportunities in niche markets.
"We've made a strong start and are actively looking to expand our offering, by providing our services to the life insurance sector, sexual health clinics, private GP surgeries and, in due course, directly to individuals."
The Innovation Centre is a 24,000 sq ft building which is home to around 80 science and technology-based businesses.
John Leake, business growth director, Sci-Tech Daresbury, said: "We're thrilled to welcome Sankey Biolabs to our campus. Frank spearheads a company that combines sharp business acumen with scientific innovation to address a key unmet need that will help companies develop better wellbeing strategies for their workforce.
"I'm confident an exciting period of growth lies ahead for the business, and our Home for Life ethos means Sci-Tech Daresbury is the perfect location for Sankey Biolabs to expand as demand rises from its target markets."